Terms: = Germ cell tumor AND MAP2K2, MEK2, 5605, ENSG00000126934, P36507, MKK2, MAPKK2, PRKMK2
41 results:
1. Genomics and Epigenomics in the Molecular Biology of Melanoma-A Prerequisite for Biomarkers Studies.
Zob DL; Augustin I; Caba L; Panzaru MC; Popa S; Popa AD; Florea L; Gorduza EV
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614156
[TBL] [Abstract] [Full Text] [Related]
2. LncRNA SNHG25 Promotes Glioma Progression Through Activating MAPK Signaling.
Wu Z; Lun P; Ji T; Niu J; Sun X; Liu X; Xu J
Mol Neurobiol; 2022 Nov; 59(11):6993-7005. PubMed ID: 36071306
[TBL] [Abstract] [Full Text] [Related]
3. Molecular alterations in retinoblastoma beyond RB1.
Mendonça V; Evangelista AC; P Matta B; M Moreira MÂ; Faria P; Lucena E; Seuánez HN
Exp Eye Res; 2021 Oct; 211():108753. PubMed ID: 34478740
[TBL] [Abstract] [Full Text] [Related]
4. An overview of binimetinib for the treatment of melanoma.
Specenier P
Expert Opin Pharmacother; 2020 May; 21(7):747-754. PubMed ID: 32100585
[TBL] [Abstract] [Full Text] [Related]
5. Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/mek2 inhibitor trametinib in patients with solid tumors.
Tolcher AW; Kurzrock R; Valero V; Gonzalez R; Heist RS; Tan AR; Means-Powell J; Werner TL; Becerra C; Wang C; Leonowens C; Kalyana-Sundaram S; Kleha JF; Gauvin J; D'Amelio AM; Ellis C; Ibrahim N; Yan L
Cancer Chemother Pharmacol; 2020 Apr; 85(4):673-683. PubMed ID: 32062691
[TBL] [Abstract] [Full Text] [Related]
6. Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAF
Kim YJ; Tsang T; Anderson GR; Posimo JM; Brady DC
Cancer Res; 2020 Apr; 80(7):1387-1400. PubMed ID: 32005716
[TBL] [Abstract] [Full Text] [Related]
7. Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy.
Olbryt M; Pigłowski W; Rajczykowski M; Pfeifer A; Student S; Fiszer-Kierzkowska A
Target Oncol; 2020 Feb; 15(1):101-113. PubMed ID: 31980996
[TBL] [Abstract] [Full Text] [Related]
8. Personalized and targeted mutational analysis of multiple second primary melanomas under kinase inhibitors.
Donati M; Zelano G; Coppola R; Cinelli E; Verri M; Persichetti P; Perrella E; Devirgiliis V; Calvieri S; Crescenzi A; Panasiti V
Ital J Dermatol Venerol; 2021 Oct; 156(5):593-598. PubMed ID: 31804055
[TBL] [Abstract] [Full Text] [Related]
9. Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by map2k2 and B2M mutations in melanoma.
Richmond CS; Vallatharasu Y; Deviley JA; Vos CR; Parsons BM; Kenny PA
Exp Mol Pathol; 2019 Oct; 110():104260. PubMed ID: 31082388
[TBL] [Abstract] [Full Text] [Related]
10. Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development.
Fuse MA; Dinh CT; Vitte J; Kirkpatrick J; Mindos T; Plati SK; Young JI; Huang J; Carlstedt A; Franco MC; Brnjos K; Nagamoto J; Petrilli AM; Copik AJ; Soulakova JN; Bracho O; Yan D; Mittal R; Shen R; Telischi FF; Morrison H; Giovannini M; Liu XZ; Chang LS; Fernandez-Valle C
Neuro Oncol; 2019 Mar; 21(4):486-497. PubMed ID: 30615146
[TBL] [Abstract] [Full Text] [Related]
11. MicroRNA-338-5p plays a tumor suppressor role in glioma through inhibition of the MAPK-signaling pathway by binding to FOXD1.
Ma XL; Shang F; Ni W; Zhu J; Luo B; Zhang YQ
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2351-2366. PubMed ID: 30225541
[TBL] [Abstract] [Full Text] [Related]
12. Trametinib (GSK1120212).
Zeiser R; Andrlová H; Meiss F
Recent Results Cancer Res; 2018; 211():91-100. PubMed ID: 30069762
[TBL] [Abstract] [Full Text] [Related]
13. Cobimetinib.
Signorelli J; Shah Gandhi A
Ann Pharmacother; 2017 Feb; 51(2):146-153. PubMed ID: 27701080
[TBL] [Abstract] [Full Text] [Related]
14. Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy.
Latimer NR; Bell H; Abrams KR; Amonkar MM; Casey M
Cancer Med; 2016 May; 5(5):806-15. PubMed ID: 27172483
[TBL] [Abstract] [Full Text] [Related]
15. Structure-Activity Relationship Study of the Neuritogenic Potential of the Glycan of Starfish Ganglioside LLG-3 (‡).
Yamagishi M; Hosoda-Yabe R; Tamai H; Konishi M; Imamura A; Ishida H; Yabe T; Ando H; Kiso M
Mar Drugs; 2015 Dec; 13(12):7250-74. PubMed ID: 26690179
[TBL] [Abstract] [Full Text] [Related]
16. MAP Kinase Pathways: Molecular Roads to Primary Acral Lentiginous Melanoma.
Fernandes JD; Hsieh R; de Freitas LA; Brandao MA; Lourenço SV; Sangueza M; Nico MM
Am J Dermatopathol; 2015 Dec; 37(12):892-7. PubMed ID: 26588333
[TBL] [Abstract] [Full Text] [Related]
17. mek2 is a prognostic marker and potential chemo-sensitizing target for glioma patients undergoing temozolomide treatment.
He H; Yao M; Zhang W; Tao B; Liu F; Li S; Dong Y; Zhang C; Meng Y; Li Y; Hu G; Luo C; Zong H; Lu Y
Cell Mol Immunol; 2016 Sep; 13(5):658-68. PubMed ID: 26189368
[TBL] [Abstract] [Full Text] [Related]
18. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.
Long GV; Fung C; Menzies AM; Pupo GM; Carlino MS; Hyman J; Shahheydari H; Tembe V; Thompson JF; Saw RP; Howle J; Hayward NK; Johansson P; Scolyer RA; Kefford RF; Rizos H
Nat Commun; 2014 Dec; 5():5694. PubMed ID: 25452114
[TBL] [Abstract] [Full Text] [Related]
19. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
Carvajal RD; Sosman JA; Quevedo JF; Milhem MM; Joshua AM; Kudchadkar RR; Linette GP; Gajewski TF; Lutzky J; Lawson DH; Lao CD; Flynn PJ; Albertini MR; Sato T; Lewis K; Doyle A; Ancell K; Panageas KS; Bluth M; Hedvat C; Erinjeri J; Ambrosini G; Marr B; Abramson DH; Dickson MA; Wolchok JD; Chapman PB; Schwartz GK
JAMA; 2014 Jun; 311(23):2397-405. PubMed ID: 24938562
[TBL] [Abstract] [Full Text] [Related]
20. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract] [Full Text] [Related]
[Next]
